Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR3 | P49019 | 1/20 | 0.34 |
| ▸ | NNMT | P40261 | 3/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13663255 | 0.80 | TRPV4 (0.39) | HCAR3 | |
| SCHEMBL824021 | 0.80 | TSHR (0.32) | — | |
| SCHEMBL16626827 | 0.80 | HCAR3 (0.44) | HCAR3NNMT | |
| SCHEMBL12690245 | 0.77 | HCAR3 (0.40) | HCAR3 | |
| SCHEMBL12690425 | 0.77 | HCAR3 (0.40) | HCAR3 | |
| SCHEMBL12690355 | 0.74 | VNN1 (0.32) | — | |
| SCHEMBL12690242 | 0.72 | HCAR3 (0.44) | HCAR3 | |
| SCHEMBL12690364 | 0.70 | HCAR3 (0.47) | HCAR3 | |
| SCHEMBL12690881 | 0.70 | ALDH1A1 (0.58) | HCAR3 | |
| SCHEMBL20462622 | 0.70 | ALDH1A1 (0.42) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9745328-B2 | Flap modulators | JANSSEN PHARMACEUTICA NV (BE) | 2017-08-29 | — | — | US | disclosed |
| US-8580825-B2 | Oxadiazole inhibitors of leukotriene production | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-11-12 | — | — | US | disclosed |
| US-20120245162-A1 | OXADIAZOLE INHIBITORS OF LEUKOTRIENE PRODUCTION | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-09-27 | — | — | US | disclosed |
| US-20120245162-A1 | OXADIAZOLE INHIBITORS OF LEUKOTRIENE PRODUCTION | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-09-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120245162-A1 | OXADIAZOLE INHIBITORS OF LEUKOTRIENE PRODUCTION | LTB4R, LTC4S, LTB4R2 | HCAR3 211/4885NNMT 3037/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.